China’s state-run medicare program recently failed to reach an agreement with Pfizer to import more Paxlovid, claiming the COVID-19 treatment drug is too expensive. This is despite the drug being offered to the state at a reduced rate in comparison with that offered to other developed countries. Lack of Paxlovid will leave only Azvudine, an anti-HIV drug the Chinese communist regime rushed through development and re-branded as an anti-COVID drug, as a treatment option.An ivermectin bottle next to a positive blood sample of COVID-19. (Novikov Aleksey/Shutterstock)Given the recent explosive spread of COVID and the resulting skyrocketing rates of hospitalization, finding...